p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Phase 2

Completed

• Conditions: High-grade Serous Ovarian Cancer
• Interventions: Drug: APR-246; Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

• Registration Number: NCT03268382
• Lead Sponsor: Aprea Therapeutics

Brief Summary

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-07-31
• Study First Submitted: 2017-08-24
• Study First Submitted QC: 2017-08-29
• Study First Posted: 2017-08-31
• Primary Completion: 2019-07-10
• Study Completion: 2019-07-10
• Results First Submitted: 2022-06-01
• Results First Submitted QC: 2022-07-19
• Results First Posted: 2022-07-21
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-27
• Last Update Posted: 2024-02-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

• Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
• Disease Progression between 4 weeks - 6 months after the last platinum-based treatment was administered
• At least a single measurable lesion
• Adequate organ function prior to registration
• Toxicities from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (defined by National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0). Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
• ECOG performance status of 0 to 2

Read More

Exclusion Criteria

• Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2
• Hypersensitivity to PLD or to any of the excipients
• Unable to undergo imaging by either CT scan or MRI
• Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
• Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
• Is taking concurrent (or within 4 weeks prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed. Palliative limited radiation therapy for pain reduction is allowed

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
APR-246 + PLD	APR-246	-
APR-246 + PLD	Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	-

Primary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR)	Up to 18 months	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Secondary Outcome Measures

Name	Time	Method
Treatment-emergent Adverse Events With Combined APR-246 and PLD Regimen	Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14)	Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.

Trial Locations

Locations (12)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol; 🇪🇸 Badalona, Spain

Centre Hospitalier Universitaire de Liège; 🇧🇪 Liège, Belgium

Imperial College London, Hammersmith Hospital Campus; 🇬🇧 London, United Kingdom

Hospital Universitario Fundación Jiménez Díaz; 🇪🇸 Madrid, Spain

The Royal Marsden NHS Foundation Trust; 🇬🇧 London, United Kingdom

Hospital Universitario HM Sanchinarro; 🇪🇸 Madrid, Spain

Medische oncologie, Universitair Ziekenhuis Gent; 🇧🇪 Gent, Belgium

Leuven University Hospitals; 🇧🇪 Leuven, Belgium

Hospital Vall d'Hebron; 🇪🇸 Barcelona, Spain

Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital; 🇬🇧 Cambridge, United Kingdom

Hospital Clinico Universitario de Valencia; 🇪🇸 Valencia, Spain

Edinburgh Cancer Research Centre, The University of Edinburgh; 🇬🇧 Edinburgh, United Kingdom